These latter events in GLI2 and MYCN further support a driver role for these genes in Shh-MB, and are clinically important as their presence in a tumor will likely render them unresponsive to Sonic Hedgehog pathway inhibition using small molecules. The gene discussed is GLI2; the disease is neoplasm.